vs
Empire State Realty Trust, Inc.（ESRT）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Empire State Realty Trust, Inc.的季度营收约是再鼎医药的1.5倍（$190.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 5.7%），过去两年再鼎医药的营收复合增速更高（20.8% vs 0.2%）
帝国州房地产信托是一家美国房地产投资信托企业，持有并运营纽约大都会区的优质办公、零售及住宅物业，旗下资产包括地标性建筑帝国大厦，主打可持续运营模式，服务各类租户及住户，专注实现长期资产增值。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ESRT vs ZLAB — 直观对比
营收规模更大
ESRT
是对方的1.5倍
$127.1M
营收增速更快
ZLAB
高出11.4%
5.7%
两年增速更快
ZLAB
近两年复合增速
0.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $190.3M | $127.1M |
| 净利润 | $3.0M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 15.5% | -54.6% |
| 净利率 | 1.6% | — |
| 营收同比 | 5.7% | 17.1% |
| 净利润同比 | -73.7% | — |
| 每股收益（稀释后） | $0.20 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESRTZLAB
| Q1 26 | $190.3M | — | ||
| Q4 25 | $199.2M | $127.1M | ||
| Q3 25 | $197.7M | $115.4M | ||
| Q2 25 | $191.3M | $109.1M | ||
| Q1 25 | $180.1M | $105.7M | ||
| Q4 24 | $197.6M | $108.5M | ||
| Q3 24 | $199.6M | $101.8M | ||
| Q2 24 | $189.5M | $100.1M |
净利润ESRTZLAB
| Q1 26 | $3.0M | — | ||
| Q4 25 | $32.2M | — | ||
| Q3 25 | $13.6M | $-36.0M | ||
| Q2 25 | $11.4M | $-40.7M | ||
| Q1 25 | $15.8M | $-48.4M | ||
| Q4 24 | $18.8M | — | ||
| Q3 24 | $22.8M | $-41.7M | ||
| Q2 24 | $28.6M | $-80.3M |
毛利率ESRTZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率ESRTZLAB
| Q1 26 | 15.5% | — | ||
| Q4 25 | 17.8% | -54.6% | ||
| Q3 25 | 19.9% | -42.3% | ||
| Q2 25 | 18.4% | -50.3% | ||
| Q1 25 | 14.3% | -53.3% | ||
| Q4 24 | 21.7% | -62.6% | ||
| Q3 24 | 22.7% | -66.6% | ||
| Q2 24 | 20.8% | -76.0% |
净利率ESRTZLAB
| Q1 26 | 1.6% | — | ||
| Q4 25 | 16.1% | — | ||
| Q3 25 | 6.9% | -31.2% | ||
| Q2 25 | 6.0% | -37.3% | ||
| Q1 25 | 8.8% | -45.8% | ||
| Q4 24 | 9.5% | — | ||
| Q3 24 | 11.4% | -40.9% | ||
| Q2 24 | 15.1% | -80.2% |
每股收益（稀释后）ESRTZLAB
| Q1 26 | $0.20 | — | ||
| Q4 25 | $0.11 | $-0.05 | ||
| Q3 25 | $0.05 | $-0.03 | ||
| Q2 25 | $0.04 | $-0.04 | ||
| Q1 25 | $0.05 | $-0.04 | ||
| Q4 24 | $0.07 | $-0.09 | ||
| Q3 24 | $0.08 | $-0.04 | ||
| Q2 24 | $0.10 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.8M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $715.5M |
| 总资产 | $4.4B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESRTZLAB
| Q1 26 | $68.8M | — | ||
| Q4 25 | $132.7M | $689.6M | ||
| Q3 25 | $154.1M | $717.2M | ||
| Q2 25 | $94.6M | $732.2M | ||
| Q1 25 | $187.8M | $757.3M | ||
| Q4 24 | $385.5M | $779.7M | ||
| Q3 24 | $421.9M | $616.1M | ||
| Q2 24 | $535.5M | $630.0M |
股东权益ESRTZLAB
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.1B | $715.5M | ||
| Q3 25 | $1.0B | $759.9M | ||
| Q2 25 | $1.0B | $791.7M | ||
| Q1 25 | $1.0B | $810.8M | ||
| Q4 24 | $1.0B | $840.9M | ||
| Q3 24 | $1.0B | $667.7M | ||
| Q2 24 | $1.0B | $704.2M |
总资产ESRTZLAB
| Q1 26 | $4.4B | — | ||
| Q4 25 | $4.5B | $1.2B | ||
| Q3 25 | $4.1B | $1.2B | ||
| Q2 25 | $4.1B | $1.2B | ||
| Q1 25 | $4.1B | $1.2B | ||
| Q4 24 | $4.5B | $1.2B | ||
| Q3 24 | $4.4B | $985.3M | ||
| Q2 24 | $4.4B | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | 10.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ESRTZLAB
| Q1 26 | — | — | ||
| Q4 25 | $249.1M | $-26.0M | ||
| Q3 25 | $105.3M | $-32.0M | ||
| Q2 25 | $26.7M | $-31.0M | ||
| Q1 25 | $83.1M | $-61.7M | ||
| Q4 24 | $260.9M | $-55.8M | ||
| Q3 24 | $102.8M | $-26.8M | ||
| Q2 24 | $37.1M | $-42.2M |
自由现金流ESRTZLAB
| Q1 26 | — | — | ||
| Q4 25 | $50.6M | $-26.7M | ||
| Q3 25 | $72.8M | $-35.0M | ||
| Q2 25 | $-55.1M | $-33.9M | ||
| Q1 25 | $41.1M | $-63.2M | ||
| Q4 24 | $88.0M | $-58.4M | ||
| Q3 24 | $-65.1M | $-28.2M | ||
| Q2 24 | $19.5M | $-42.9M |
自由现金流率ESRTZLAB
| Q1 26 | — | — | ||
| Q4 25 | 25.4% | -21.0% | ||
| Q3 25 | 36.8% | -30.4% | ||
| Q2 25 | -28.8% | -31.1% | ||
| Q1 25 | 22.8% | -59.9% | ||
| Q4 24 | 44.5% | -53.8% | ||
| Q3 24 | -32.6% | -27.7% | ||
| Q2 24 | 10.3% | -42.9% |
资本支出强度ESRTZLAB
| Q1 26 | 10.0% | — | ||
| Q4 25 | 99.6% | 0.5% | ||
| Q3 25 | 16.5% | 2.6% | ||
| Q2 25 | 42.8% | 2.6% | ||
| Q1 25 | 23.4% | 1.5% | ||
| Q4 24 | 87.5% | 2.4% | ||
| Q3 24 | 84.1% | 1.3% | ||
| Q2 24 | 9.3% | 0.7% |
现金转化率ESRTZLAB
| Q1 26 | — | — | ||
| Q4 25 | 7.74× | — | ||
| Q3 25 | 7.72× | — | ||
| Q2 25 | 2.35× | — | ||
| Q1 25 | 5.27× | — | ||
| Q4 24 | 13.88× | — | ||
| Q3 24 | 4.51× | — | ||
| Q2 24 | 1.30× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESRT
| Rental revenue (1) | $166.1M | 87% |
| Observatory revenue | $18.5M | 10% |
| Other revenue and fees | $4.1M | 2% |
| Lease termination fees | $1.4M | 1% |
| Third-party management and other fees | $277.0K | 0% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
